<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813435</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-12-001, 02EU11</org_study_id>
    <nct_id>NCT01813435</nct_id>
  </id_info>
  <brief_title>GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation</brief_title>
  <official_title>Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-eluting Stent Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosensors International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a stent procedure, it is common practice to prescribe anti-platelet medication to
      prevent the blood from clotting. The main objective of this study is to determine if there
      is a better medication strategy to prevent blood from clotting and at the same time
      minimising the number of complications.

      There are two medication strategies:

        -  Study group: Dual anti-platelet therapy (ticagrelor combined with aspirin) for 1 month,
           and then ticagrelor alone for another 23 months OR

        -  Control group: Standard treatment, being dual anti-platelet therapy (ticagrelor or
           clopidogrel combined with aspirin) for 12 months, and then aspirin alone indefinitely
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to determine in all-comers patients undergoing PCI under standardised
      treatment (including the BioMatrix family of drug-eluting stents and bivalirudin), whether
      treatment with 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor
      monotherapy is superior with respect to the composite of all-cause mortality or non-fatal
      new Q-wave MI compared to treatment with 12 months of standard dual anti platelet therapy
      (DAPT) followed by aspirin monotherapy.

      The study design is an investigator-initiated, prospective randomised, multi-centre,
      multi-national, open-label trial to be conducted in approximately 60-80 interventional
      cardiology centres in Europe, North America, South America and Asia-Pacific. Patients will
      be randomised at a 1:1 ratio to study or reference treatment strategy.

      Randomisation will occur at the time of the index procedure prior to PCI. Subjects will be
      stratified according to centre and according to the clinical presentation (Stable Coronary
      Artery Disease (CAD) vs. Acute Coronary Syndrome (ACS)).

      All patients will be followed for a period of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite of all-cause mortality or non-fatal new Q-wave MI</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The composite of investigator-reported BARC3 or BARC5 bleeding according to BARC definitions up to 2 years post randomisation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Additional Endpoints</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Endpoints</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Non-fatal new Q-wave MI</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Endpoint</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Ischemic stroke, including stroke of undetermined cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Endpoint</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Haemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Endpoint</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite of all-cause mortality, stroke and non-fatal new Q-wave MI</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Endpoints</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Coronary revascularisation</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Endpoint</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite Stent Thrombosis according to the Academic Research Consortium</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Experimental treatment strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.
Dosage and frequency:
Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference treatment strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.
Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.
Dosage and frequency:
Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.</description>
    <arm_group_label>Experimental treatment strategy</arm_group_label>
    <arm_group_label>Reference treatment strategy</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic Acid</intervention_name>
    <description>Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy</description>
    <arm_group_label>Experimental treatment strategy</arm_group_label>
    <arm_group_label>Reference treatment strategy</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>B01AC06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Active Comparator:   Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.
Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy</description>
    <arm_group_label>Reference treatment strategy</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>B01AC04</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -&quot;All comer&quot; patients

          1. Age ≥18 years;

          2. Presence of one or more coronary artery stenoses of 50% or more in a native coronary
             artery or in a saphenous venous or arterial bypass conduit suitable for coronary
             stent implantation. The vessel should have a reference vessel diameter of at least
             2.25 mm (no limitation on the number of treated lesions, vessels, or lesion length);

          3. Able to provide informed consent and willing to participate in 2 year follow- up
             period.

        Exclusion Criteria:

          1. Known intolerance to aspirin, P2Y12 inhibitors, bivalirudin, stainless steel or
             biolimus;

          2. Known intake of a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin,
             nefazodone, ritonavir, and atazanavir), as co-administration may lead to a
             substantial increase in exposure to ticagrelor;

          3. Known  moderate to severe hepatic impairment (alanine-aminotransferase ≥ 3 x ULN);

          4. Planned surgery, including CABG as a staged procedure (hybrid) within 12 months of
             the index procedure, unless dual antiplatelet therapy is maintained throughout the
             peri-surgical period;

          5. Need for chronic oral anti-coagulation therapy;

          6. Active major bleeding or major surgery within the last 30 days;

          7. Known history of intracranial haemorrhagic stroke or intra-cranial aneurysm;

          8. Known stroke (any type) within the last 30 days;

          9. Known pregnancy at time of randomisation;

         10. Currently participating in another trial and not yet at its primary endpoint.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Serruys, Prof. MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Thoraxcenter, Erasmus, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Valgimigli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaria di Ferrara, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Vranckx, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Virga Jesse Ziekenhuis, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Windecker, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital, University Hospital Bern Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Hamm, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik GmbH, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Juni, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Steg, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>C.H.U. Bichat - Claude Bernard, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerrit-Anne van Es</last_name>
    <role>Study Director</role>
    <affiliation>ECRI, the Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marieke Tuinman, MSc.</last_name>
    <phone>+31654697953</phone>
    <email>mtuinman@cardialysis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Korthout, MSc.</last_name>
    <phone>+31613230639</phone>
    <email>lkorthout@cardialysis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Metzler, Prof. MD</last_name>
      <phone>43-512-504-81315</phone>
      <email>Bernhard.Metzler@uki.at</email>
    </contact>
    <investigator>
      <last_name>Otmar Pachinger, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Metzler, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clemens Steinwerder, Prof. dr.</last_name>
      <phone>4373278066620</phone>
      <email>clemens.steinwender@akh.linz.at</email>
    </contact>
    <investigator>
      <last_name>Clemens Steinwender, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital AKH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Delle Karth, Prof. MD</last_name>
      <phone>+4340400 4615</phone>
      <email>georg.delle-karth@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Georg Delle Karth, Prof. MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Huber, Prof.</last_name>
      <phone>431491505761</phone>
      <email>kurt.huber@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Kurt Huber, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Henegouwen</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adel Aminian, Dr.</last_name>
      <phone>+32477676405</phone>
      <email>adel.aminian@chu-charleroi.be</email>
    </contact>
    <investigator>
      <last_name>Adel Amininian, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedwig Batjoens</last_name>
      <phone>+32 53 72 41 68</phone>
      <email>cardio.studie.aalst@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Emanuel Barbato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Janssens, Dr.</last_name>
      <phone>3215505140</phone>
      <email>luc.janssens@imelda.be</email>
    </contact>
    <investigator>
      <last_name>Luc Janssens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZOL St.Jan</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Vrolix</last_name>
      <phone>+3289327100</phone>
      <email>mathias.vrolix@zol.be</email>
    </contact>
    <investigator>
      <last_name>Mathias Vrolix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virga Jesse</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Benit, Dr.</last_name>
      <phone>3211309589</phone>
      <email>edouard.benit@virgajesse.be</email>
    </contact>
    <investigator>
      <last_name>Edouard Benit, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual Cardiologia Aloisio de Castro</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edgard Freitas Quintella, MD</last_name>
      <phone>+55 21 22462567</phone>
      <email>e.quintella@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Edgard Freitas Quintella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>sergio martins leandro</last_name>
      <phone>+55 21 86261000</phone>
      <email>sergiom.leandro@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Sergio Leandro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Naval Marcílio</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MARIA CRISTINA MEIRA FERREIRA, MD</last_name>
      <phone>+552125995455</phone>
      <email>macrisferreira@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>&quot;MARIA CRISTINA MEIRA FERREIRA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Incor - Hcfmusp</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SELMA CRISTINA QUAIA</last_name>
      <phone>+551126615960</phone>
      <email>selma.quaia@incor.usp.br</email>
    </contact>
    <investigator>
      <last_name>P. Lemos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renata Viana</last_name>
      <phone>+551150856325</phone>
      <email>rviana@dantepazzanese.org.br</email>
    </contact>
    <investigator>
      <last_name>Amanda Sousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituo Do Coracao Do Triangulo Mineiro</name>
      <address>
        <city>Uberlândia</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Cunha</last_name>
      <phone>+553432355207 #31</phone>
      <email>silvia@ict.med.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Botelho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Robbins</last_name>
      <phone>+9052365966</phone>
      <email>kim.yorkpci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sylvain Plante</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill Hospital</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Amedee</last_name>
      <phone>514 843-1502</phone>
      <email>kathleen.amedee@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Luc Bilodeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quebec Heart-Lung Institute</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Jadin</last_name>
      <phone>14186568711 #3007</phone>
      <email>michele.jadin@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Olivier F. Bertrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital - Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lene Kløvgaard</last_name>
      <phone>0045 3545 1191</phone>
      <email>lene.kloevgaard@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lene Holmvang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital - Gentofte</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Soeren Galatius, MD</last_name>
      <phone>+4521638907</phone>
      <email>soga@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Soeren Galatius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Dômes</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Caillot, MD</last_name>
      <phone>+33680585645</phone>
      <email>n.caillot@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Janusz Lipiecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J. Cartier Institut ICPS</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L. MORSIANI</last_name>
      <phone>+331 69 85 50 89</phone>
      <email>l.morsiani@icps.com.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Claude Morice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel STEG, Prof. MD</last_name>
      <phone>+33140258669</phone>
      <email>gabriel.steg@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel STEG, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mondor</name>
      <address>
        <city>Paris / Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Chevalier-Bidaud</last_name>
      <phone>+33149 812678</phone>
      <email>brigitte.chevalier-bidaud@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Teiger, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rangueil Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JACQUELINE CAHUZAC</last_name>
      <phone>+33561323345</phone>
      <email>cahuzac.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Carrie, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric PETIT</last_name>
      <phone>+33562211699</phone>
      <email>f.petit@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Jean FAJADET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad-Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregor Leibundgut, MD</last_name>
      <phone>+4976334024282</phone>
      <email>gregor.leibundgut@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Franz-Josef Neumann, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Heart Center</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Möllmann, Prof. MD</last_name>
      <phone>+4960329962246</phone>
      <email>h.moellmann@kerckhoff-klinik.de</email>
    </contact>
    <investigator>
      <last_name>Helge Möllmann, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. H. Strasser, Prof. MD</last_name>
      <phone>+493514501330</phone>
      <email>Ruth.Strasser@tu-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>K. Haacke</last_name>
    </contact_backup>
    <investigator>
      <last_name>R. H. Strasser, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Cardiovascular Center Rhein Ruhr</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliasbeth Blank</last_name>
      <phone>+4920189786223</phone>
      <email>e.blank@contilia.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Naber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Ulbricht</last_name>
      <phone>+49661845381</phone>
      <email>med1.sek@klinikum-fulda.de</email>
    </contact>
    <investigator>
      <last_name>Volker Schächinger, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Giessen</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nef, Prof. MD</last_name>
      <phone>0049 641 985 56684</phone>
      <email>holger.nef@me.com</email>
    </contact>
    <investigator>
      <last_name>Christiaan Hamm, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Schillinger, Prof. MD</last_name>
      <phone>+49551396372</phone>
      <email>schiwolf@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Schillinger, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut-Achdorf</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U. Zrenner</last_name>
      <phone>+49871-404 2149</phone>
      <email>ute.zrenner@kh-landshut-achdorf.de, andrea.ruehle@kh-landshut-achdorf.de</email>
    </contact>
    <contact_backup>
      <last_name>A. Rühle</last_name>
      <phone>+49871-404 2177</phone>
    </contact_backup>
    <investigator>
      <last_name>Bernhard Zrenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Donato</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KENNETH DUCCI</last_name>
      <phone>575254070</phone>
      <email>kducci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>LEONARDO BOLOGNESE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monia Monti</last_name>
      <phone>+390532237227</phone>
      <email>mntmno@unife.it</email>
    </contact>
    <investigator>
      <last_name>Marco Valgimigli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Montevergine</name>
      <address>
        <city>Mercogliano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugenio Stabile</last_name>
      <phone>+39825705130</phone>
      <email>eugeniostabile@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paulo Rubino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>angela ferrari</last_name>
      <phone>+390226437331</phone>
      <email>ferrari.angela@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratorio Emodinamica</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umberto Canosi</last_name>
      <phone>+390382503739</phone>
      <email>laboratorio.emodinamica@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Ezio Bramucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Maria</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcello Dominici, Prof. MD</last_name>
      <phone>+393299039039</phone>
      <email>md.dominici@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcello Dominici, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RJ van Geuns, MD</last_name>
      <phone>0031-10-7032891</phone>
      <email>r.vangeuns@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>R. van Geuns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V Umans, MD</last_name>
      <phone>+31725484444</phone>
      <email>v.umans@mca.nl</email>
    </contact>
    <investigator>
      <last_name>V Umans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T Slagboom, MD</last_name>
      <phone>+31205994824</phone>
      <email>T.Slagboom@OLVG.nl</email>
    </contact>
    <investigator>
      <last_name>T Slagboom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Metske van der Wal</last_name>
      <phone>31582863123</phone>
      <email>metske.wal@znb.nl</email>
    </contact>
    <investigator>
      <last_name>A.J. van Boven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Suryapranata, Prof. MD</last_name>
      <phone>+31611759514</phone>
      <email>h.suryapranata@cardio.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>Harry Suryapranata, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ria van Vliet</last_name>
      <phone>+31102913278</phone>
      <email>VlietM@maasstadziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Kees-Jan Royaards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAKS Chrzanów</name>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander Zurakowski, MD</last_name>
      <phone>+48605 336127</phone>
      <email>olekzurakowski@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aleksander Zurakowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAKS Dabrowa</name>
      <address>
        <city>Dabrowa Gornicza</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dagmara Oleksiak</last_name>
      <phone>+48327642724</phone>
      <email>d.oleksiak@klinikiserca.pl</email>
    </contact>
    <investigator>
      <last_name>Paweł Buszman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAKS Kozle</name>
      <address>
        <city>Kedzierzyn-Kozle</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grażyna Zalewska</last_name>
      <phone>+48774722565</phone>
      <email>g.zalewska@klinikiserca.pl</email>
    </contact>
    <investigator>
      <last_name>Janusz Prokopczuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JP2</name>
      <address>
        <city>Krakov</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaroslaw Trebacz</last_name>
      <phone>+48504299395</phone>
      <email>jtrebacz@szpitaljp2.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Żmudka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrzej Dreawnicki</last_name>
      <phone>+48618549223</phone>
      <email>drewnicki@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Maciej Lesiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAKS Ustron</name>
      <address>
        <city>Ustroń</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marek Król, MD</last_name>
      <phone>+48338545857</phone>
      <email>drkrol@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marek Król, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maciej Dąbrowski, MD</last_name>
      <phone>+48223434267</phone>
      <email>macidabro@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Heart Center</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence</last_name>
      <phone>+6564367686</phone>
      <email>florence.ang.s.c@nhcs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Tian Hai Koh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Ong, MD</last_name>
      <phone>+6563577831</phone>
      <email>paul_jl_ong@ttsh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Paul Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sant Pau i Santa Creu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan García-Picart</last_name>
      <phone>+34935565851</phone>
      <email>jgarciapi@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Antonio Serra Peñaranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic University Hospital Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Trelliso</last_name>
      <phone>+34932279305</phone>
      <email>etrelliso@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Manel Sabate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Guerrero</last_name>
      <phone>+34932607229</phone>
      <email>sonia.guerrero.moreno@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angel Cequier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Fernandez Ortiz</last_name>
      <phone>+34 913303289</phone>
      <email>afernandez.hcsc@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Carlos Macaya Miguel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 Octobre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALFONSO JURADO</last_name>
      <phone>+34913908440</phone>
      <email>alfonjroman@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>AGUSTIN ALBARRAN GONZALEZ-TREVILLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Marques de Valdecilla Santander</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Zueco, MD</last_name>
      <phone>+34942202744</phone>
      <email>jzueco@humv.es</email>
    </contact>
    <investigator>
      <last_name>Javier Zueco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Diaz</last_name>
      <phone>+34986811163</phone>
      <email>carlos.maria.diaz.lopez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Andres Iñiguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan James, MD</last_name>
      <phone>+46705944404</phone>
      <email>stefan.james@ucr.uu.se</email>
    </contact>
    <investigator>
      <last_name>Stefan James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Windecker, Prof. MD</last_name>
      <phone>+41316324497</phone>
      <email>stephan.windecker@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stephan Windecker, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HUG</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Roffi, MD</last_name>
      <phone>+41 22 37 23 743</phone>
      <email>marco.roffi@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Marco Roffi, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nathalie Lauriers</last_name>
      <phone>41795560618</phone>
      <email>nathalie.lauriers@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Eric Eeckhout, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioCentro Ticino</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossi M Grazia</last_name>
      <phone>+41918053055</phone>
      <email>src@cardiocentro.org</email>
    </contact>
    <investigator>
      <last_name>Tiziano Moccetti, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Bühler</last_name>
      <phone>+41442553049</phone>
      <email>ines.buehler@usz.ch</email>
    </contact>
    <investigator>
      <last_name>R. Binder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Blackburn Hospital</name>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scot Garg</last_name>
      <phone>+447977408384</phone>
      <email>scot.garg@elht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Scot Garg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LANCASHIRE HEART CENTRE, Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavin Galasko, MD</last_name>
      <phone>+44 1253 657761</phone>
      <email>dr.galasko@bfwhospitals.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Gavin Galasko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Cooter</last_name>
      <phone>01273 696955</phone>
      <email>nina.cooter@bsuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Daivd Hildick-Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Heart Institute</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Baumbach, MD</last_name>
      <phone>+1173426573</phone>
      <email>andreas.baumbach@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Andreas Baumbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Anderson, MD</last_name>
      <phone>02920 743786</phone>
      <email>Richard.Anderson@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith G Oldroyd, MD</last_name>
      <phone>0141 951 5180</phone>
      <email>keith.oldroyd@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Keith G. Oldroyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rod Stables, MD</last_name>
      <phone>+44 151 600 1489</phone>
      <email>rod.stables@LHCH.nhs.Uk</email>
    </contact>
    <investigator>
      <last_name>Rod Stables, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Manchester University Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Daniel</last_name>
      <phone>+44 161 291 4650</phone>
      <email>diane.daniel@uhsm.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Saqib Chowdhary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Iles-Smith</last_name>
      <phone>+1612767958</phone>
      <email>Heather.Iles-smith@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mamas Mamas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 12, 2013</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>ACS</keyword>
  <keyword>All comers</keyword>
  <keyword>DAPT</keyword>
  <keyword>PCI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
